IDIOPATHIC PULMONARY FIBROSIS
Clinical trials for IDIOPATHIC PULMONARY FIBROSIS explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC PULMONARY FIBROSIS trials appear
Sign up with your email to follow new studies for IDIOPATHIC PULMONARY FIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lung fibrosis drug trial halted early: what happened?
Disease control TerminatedThis study tested an experimental drug called HZN-825 in people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing hard. The trial aimed to see if the drug could slow lung function decline over 52 weeks. About 153 adults with…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated May 17, 2026 06:51 UTC
-
New IPF drug trial halted: what happened?
Disease control TerminatedThis study tested a new medicine called GSK3915393 for people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. The trial aimed to see if the drug could slow lung function decline, but it was terminated early. About 15…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated May 17, 2026 06:49 UTC
-
Promising lung fibrosis drug study halted early
Disease control TerminatedThis study tested new single treatments for idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing problems. It included 46 adults aged 40 and older with mild to moderate IPF. The study was stopped early, so results are limited.
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
Lung scarring drug trial halted midway – what we know
Disease control TerminatedThis study tested a drug called vixarelimab to see if it could improve lung function in people with two types of lung scarring: idiopathic pulmonary fibrosis (IPF) and lung scarring linked to scleroderma (SSc-ILD). About 286 adults took either the drug or a placebo for 52 weeks, …
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New drug aims to quiet chronic cough in lung disease patients
Symptom relief TerminatedThis study tested an experimental drug called BI 1839100 to see if it could reduce chronic coughing in adults with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Participants took different doses of the drug or a placebo for 12 weeks. Coughing was me…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Symptom relief
Last updated May 17, 2026 07:04 UTC
-
Sleep apnea treatment studied for IPF patients – but study stopped early
Knowledge-focused TerminatedThis study looked at whether CPAP, a machine that helps with breathing during sleep, could reduce acid reflux and lung inflammation in people with idiopathic pulmonary fibrosis (IPF) who also have sleep apnea. The goal was to measure changes in certain biomarkers linked to lung d…
Matched conditions: IDIOPATHIC PULMONARY FIBROSIS
Phase: NA • Sponsor: University of Arizona • Aim: Knowledge-focused
Last updated May 17, 2026 06:52 UTC